The flavoprotein FOXRED2 reductively activates nitro- chloromethylbenzindolines and other hypoxia-targeting prodrugs

Biochemical Pharmacology

Volumn 89, Issue 2, 2014, Pages 224-235

  Hunter, Francis W ^a   Jaiswal, Jagdish K ^a   Hurley, Daniel G ^b,c   Liyanage, H D Sarath ^a   McManaway, Sarah P ^a   Gu, Yongchuan ^a   Richter, Susan ^a   Wang, Jingli ^a   Tercel, Moana ^a,c   Print, Cristin G ^b,c   Wilson, William R ^a,c   Pruijn, Frederik B ^a,c  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c MAURICE WILKINS CENTRE FOR MOLECULAR BIODISCOVERY   (New Zealand)

Author keywords

FOXRED2; Hypoxia targeting prodrug; NitroCBI; PR 104; TH 302; Tirapazamine

Indexed keywords

5 METHYLTETRAHYDROFOLATE HOMOCYSTEINE METHYLTRANSFERASE REDUCTASE; CYTOCHROME P450 REDUCTASE; DIPHENYLIODONIUM SALT; FLAVOPROTEIN; FOXRED 2 PROTEIN; N,N' BIS(2 BROMOETHYL)PHOSPHORODIAMIDIC ACID (1 METHYL 2 NITRO 1H IMIDAZOL 5 YL)METHYL ESTER; NITRO CHLOROMETHYLBENZINDOLINE; OXIDOREDUCTASE; PR 104A; PRODRUG; SN 29428; SN 30000; TIRAPAZAMINE; UNCLASSIFIED DRUG; ZINC FINGER NUCLEASE;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG ACTIVATION; DRUG CYTOTOXICITY; EMBRYO; ENZYME ACTIVITY; GENE INACTIVATION; HUMAN; HUMAN CELL; HYPOXIA; MASS FRAGMENTOGRAPHY; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; XENOBIOTIC METABOLISM;

FOXRED2; HYPOXIA-TARGETING PRODRUG; NITROCBI; PR-104; TH-302; TIRAPAZAMINE;

CELL HYPOXIA; CYCLIC N-OXIDES; FLAVOPROTEINS; HCT116 CELLS; HEK293 CELLS; HEP G2 CELLS; HUMANS; INDOLES; OXIDATION-REDUCTION; OXIDOREDUCTASES; PRODRUGS; TRIAZINES;

EID: 84899457375     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2014.03.001     Document Type: Article

References (51)

1. W.R. Wilson, and M.P. Hay Targeting hypoxia in cancer therapy Nat Rev Cancer 11 2011 393 410
2. A.M. Shannon, D.J. Bouchier-Hayes, C.M. Condron, and D. Toomey Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies Cancer Treat Rev 29 2003 297 307
3. P. Vaupel, and A. Mayer Hypoxia in cancer: significance and impact on clinical outcome Cancer Metastasis Rev 26 2007 225 239
4. F. Meng, J.W. Evans, D. Bhupathi, M. Banica, L. Lan, and G. Lorente et al. Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302 Mol Cancer Ther 11 2012 740 751
5. A.V. Patterson, D.M. Ferry, S.J. Edmunds, Y. Gu, R.S. Singleton, and K. Patel et al. Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104 Clin Cancer Res 13 2007 3922 3932
6. K.O. Hicks, B.G. Siim, J.K. Jaiswal, F.B. Pruijn, A.M. Fraser, and R. Patel et al. Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors Clin Cancer Res 16 2010 4946 4957
7. E.M. Zeman, J.M. Brown, M.J. Lemmon, V.K. Hirst, and W.W. Lee SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells Int J Radiat Oncol Biol Phys 12 1986 1239 1242
8. M. Tercel, G.J. Atwell, S. Yang, A. Ashoorzadeh, R.J. Stevenson, and K.J. Botting et al. Selective treatment of hypoxic tumor cells in vivo: phosphate pre-prodrugs of nitro analogues of the duocarmycins Angew Chem Int Ed 50 2011 2606 2609
9. W.R. Wilson, S.M. Stribbling, F.B. Pruijn, S.P. Syddall, A.V. Patterson, and H.D.S. Liyanage et al. Nitro-chloromethylbenzindolines: hypoxia-activated prodrugs of potent adenine N3 DNA minor groove alkylators Mol Cancer Ther 8 2009 2903 2913
10. N. Pavlidis, S. Aamdal, A. Awada, H. Calvert, P. Fumoleau, and R. Sorio et al. Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG) Cancer Chemother Pharmacol 46 2000 167 171
11. D.L. Boger, and D.S. Johnson CC-1065 and the duocarmycins: understanding their biological function through mechanistic studies Angew Chem Int Ed 35 1996 1439 1474
12. M.S. Tichenor, and D.L. Boger Yatakemycin: total synthesis, DNA alkylation, and biological properties Nat Prod Rep 25 2008 220 226
13. M. Tercel, W.A. Denny, and W.R. Wilson Nitrogen and sulfur analogues of the seco-CI alkylating agent: synthesis and cytotoxicity Bioorg Med Chem Lett 6 1996 2735 2740
14. G.J. Atwell, M. Tercel, M. Boyd, W.R. Wilson, and W.A. Denny Synthesis and cytotoxicity of 5-amino-1-(chloromethyl)-3-[(5,6,7-trimethoxyindol-2-yl) carbonyl], 1,2 dihydro-3H-benz[e]indole (Amino-seco-CBI-TMI) and related 5-alkylamino analogues: new DNA minor groove alkylating agents J Org Chem 63 1998 9414 9420
15. M. Tercel, M.A. Gieseg, W.A. Denny, and W.R. Wilson Synthesis and cytotoxicity of amino-seco-DSA: an amino analogue of the DNA alkylating agent duocarmycin SA J Org Chem 64 1999 5946 5953
16. M.A. Gieseg, J. Matejovic, and W.A. Denny Comparison of the patterns of DNA alkylation by phenol and amino seco-CBI-TMI compounds: use of a PCR method for the facile preparation of single end-labelled double-stranded DNA Anticancer Drug Des 14 1999 77 84
17. C.P. Guise, M.R. Abbattista, S.R. Tipparaju, N.K. Lambie, J. Su, and D. Li et al. Diflavin oxidoreductases activate the bioreductive prodrug PR-104A under hypoxia Mol Pharmacol 81 2012 31 40
18. C.P. Guise, A.T. Wang, A. Theil, D.J. Bridewell, W.R. Wilson, and A.V. Patterson Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH:cytochrome P450 oxidoreductase under hypoxia Biochem Pharmacol 74 2007 810 820
19. J. Wang, C.P. Guise, H.-L. Hsu, D. Hurley, W.R. Wilson, and A.V. Patterson Abstract 2111: identification of reductases capable of metabolic activation of hypoxia targeting prodrug SN30000 and hypoxia marker EF5 AACR 104th Annual Meeting 2013 2013
20. P. Wardman Electron transfer and oxidative stress as key factors in the design of drugs selectively active in hypoxia Curr Med Chem 8 2001 739 761
21. J. Su, Y. Gu, F.B. Pruijn, J.B. Smaill, A.V. Patterson, and C.P. Guise et al. Zinc finger nuclease knockout of NADPH:cytochrome P450 oxidoreductase (POR) in human tumour cell lines demonstrates that hypoxia-activated prodrugs differ in POR dependence J Biol Chem 288 2013 37138 37153
22. H.A. Seow, P.G. Penketh, K. Shyam, S. Rockwell, and A.C. Sartorelli 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[[1-(4-nitrophenyl)ethoxy] carbonyl]hydrazine: an anticancer agent targeting hypoxic cells Proc Natl Acad Sci USA 102 2005 9282 9287
23. D.L. Gustafson, H.D. Beall, E.M. Bolton, D. Ross, and C.A. Waldren Expression of human NAD(P)H:quinone oxidoreductase (DT-diaphorase) in Chinese hamster ovary cells: effect on the toxicity of antitumor quinones Mol Pharmacol 50 1996 728 735
24. C.P. Guise, M.R. Abbattista, R.S. Singleton, S.D. Holford, J. Connolly, and G.U. Dachs et al. The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3 Cancer Res 70 2010 1573 1584
25. J. Riemer, C. Appenzeller-Herzog, L. Johansson, B. Bodenmiller, R. Hartmann-Petersen, and L. Ellgaard A luminal flavoprotein in endoplasmic reticulum-associated degradation Proc Natl Acad Sci USA 106 2009 14831 14836
26. F.W. Hunter, J. Wang, R. Patel, H.L. Hsu, A.J.R. Hickey, and M.P. Hay et al. Homologous recombination repair-dependent cytotoxicity of the benzotriazine di-N-oxide CEN-209: comparison with other hypoxia-activated prodrugs Biochem Pharmacol 83 2012 574 585
27. M. Boyd, M.P. Hay, and P.D.W. Boyd Complete 1H, 13C and 15N NMR assignment of tirapazamine and related 1,2,4-benzotriazine N-oxides Magn Reson Chem 44 2006 948 954
28. M. Tercel, H.H. Lee, S. Yang, H.D.S. Liyanage, S.Y. Mehta, and P.D.W. Boyd et al. Preparation and antitumour properties of the enantiomers of a hypoxia-selective nitro analogue of the duocarmycins ChemMedChem 6 2011 1860 1871
29. Y. Gu, A.V. Patterson, G.J. Atwell, S.B. Chernikova, J.M. Brown, and L.H. Thompson et al. Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A Mol Cancer Ther 8 2009 1714 1723
30. J. Wang, A. Foehrenbacher, J. Su, R. Patel, M.P. Hay, and K.O. Hicks et al. The 2-nitroimidazole EF5 is a biomarker for oxidoreductases that activate the bioreductive prodrug CEN-209 under hypoxia Clin Cancer Res 18 2012 1684 1695
31. Y. Gu, and W.R. Wilson Rapid and sensitive ultra-high-pressure liquid chromatography-tandem mass spectrometry analysis of the novel anticancer agent PR-104 and its major metabolites in human plasma: application to a pharmacokinetic study J Chromat B: Analyt Technol Biomed Life Sci 877 2009 3181 3186
32. R.C. Gentleman, V.J. Carey, D.M. Bates, B. Bolstad, M. Dettling, and S. Dudoit et al. Bioconductor: open software development for computational biology and bioinformatics Genome Biol 5 2004 R80
33. R.A. Irizarry, B.M. Bolstad, F. Collin, L.M. Cope, B. Hobbs, and T.P. Speed Summaries of Affymetrix GeneChip probe level data Nucleic Acids Res 31 2003 e15
34. G.M. Marchetti Independencies induced from a graphical Markov model after marginalization and conditioning: the R package ggm J Stat Softw 15 2006 1 15
35. J. Su, C.P. Guise, and W.R. Wilson FSL-61 is a 6-nitroquinolone fluorogenic probe for one-electron reductases in hypoxic cells Biochem J 452 2013 79 86
36. D.G. Tew Inhibition of cytochrome P450 reductase by the diphenyliodonium cation. Kinetic analysis and covalent modifications Biochemistry 32 1993 10209 10215
37. V.B. O'Donnell, G.C.M. Smith, and O.T.G. Jones Involvement of phenyl radicals in iodonium compound inhibition of flavoenzymes Mol Pharmacol 46 1994 778 785
38. J. Riemer, H.G. Hansen, C. Appenzeller-Herzog, L. Johansson, and L. Ellgaard Identification of the PDI-family member ERp90 as an interaction partner of ERFAD PLoS ONE 6 2011 e17037
39. S. Shim, W. Lee, H. Chung, and Y.K. Jung Amyloid β-induced FOXRED2 mediates neuronal cell death via inhibition of proteasome activity Cell Mol Life Sci 68 2011 2115 2127
40. B.G. Wouters, and M. Koritzinsky Hypoxia signalling through mTOR and the unfolded protein response in cancer Nat Rev Cancer 8 2008 851 864
41. W.R. Wilson, K.O. Hicks, S.M. Pullen, D.M. Ferry, N.A. Helsby, and A.V. Patterson Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards Rad Res 167 2007 625 636
42. R.F. Anderson, S.S. Shinde, M.P. Hay, S.A. Gamage, and W.A. Denny Activation of 3-amino-1,2,4-benzotriazine 1,4-dioxide antitumor agents to oxidizing species following their one-electron reduction J Am Chem Soc 125 2003 748 756
43. E.Y. Tan, M. Yan, L. Campo, C. Han, E. Takano, and H. Turley et al. The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy Br J Cancer 100 2009 405 411
44. M.J. Voss, M.F. Möller, D.G. Powe, B. Niggemann, K.S. Zänker, and F. Entschladen Luminal and basal-like breast cancer cells show increased migration induced by hypoxia, mediated by an autocrine mechanism BMC Cancer 11 2011 158
45. V.M. Neumeister, C.A. Sullivan, R. Lindner, K. Lezon-Geyda, J. Li, and J. Zavada et al. Hypoxia-induced protein CAIX is associated with somatic loss of BRCA1 protein and pathway activity in triple negative breast cancer Breast Cancer Res Treat 136 2012 67 75
46. C. Dong, T. Yuan, Y. Wu, Y. Wang, T.M. Fan, and S. Miriyala et al. Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer Cancer Cell 23 2013 316 331
47. T.C.G.A. Network Comprehensive molecular portraits of human breast tumours Nature 490 2012 61 70
48. D. Zardavas, J. Baselga, and M. Piccart Emerging targeted agents in metastatic breast cancer Nat Rev Clin Oncol 10 2013 191 210
49. B.A. Teicher, J.S. Lazo, and A.C. Sartorelli Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells Cancer Res 41 1981 73 81
50. B. Jonsson, and J. Bergh Hurdles in anticancer drug development from a regulatory perspective Nat Rev Clin Oncol 9 2012 236 243
51. T. Takadate, T. Onogawa, T. Fukuda, F. Motoi, T. Suzuki, and K. Fujii et al. Novel prognostic protein markers of resectable pancreatic cancer identified by coupled shotgun and targeted proteomics using formalin-fixed paraffin-embedded tissues Int J Cancer 132 2013 1368 1382